Login to Your Account

Near-Term Focus on Off-Label Sales

FTC Alleges Cephalon's Deals Blocked Generics from Market

By Jennifer Boggs

Friday, February 15, 2008
Alleging a "course of anticompetitive conduct," the Federal Trade Commission filed a complaint against Cephalon Inc. regarding deals signed two years ago between the firm and four generic manufacturers to keep lower-cost generic versions of its flagship narcolepsy drug, Provigil, from reaching the market until 2012. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription